^ abWiesfeld AC, Crijns HJ, Bergstrand RH, Almgren O, Hillege HL, Lie KI (October 1993). "Torsades de pointes with Almokalant, a new class III antiarrhythmic drug". American Heart Journal. 126 (4): 1008–1011. doi:10.1016/0002-8703(93)90726-p. PMID8213422.
^Wellfelt K, Sköld AC, Wallin A, Danielsson BR (1999-04-01). "Teratogenicity of the class III antiarrhythmic drug almokalant. Role of hypoxia and reactive oxygen species". Reproductive Toxicology. 13 (2): 93–101. Bibcode:1999RepTx..13...93W. doi:10.1016/s0890-6238(98)00066-5. PMID10213516.